Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Human acute myeloid leukemia blast-derived exosomes in patient-derived xenograft mice mediate immune suppression.

Hong CS, Danet-Desnoyers G, Shan X, Sharma P, Whiteside TL, Boyiadzis M.

Exp Hematol. 2019 Jul 29. pii: S0301-472X(19)30918-X. doi: 10.1016/j.exphem.2019.07.005. [Epub ahead of print]

PMID:
31369790
2.

Psychosocial Experiences of Young Adults Diagnosed With Acute Leukemia During Hospitalization for Induction Chemotherapy Treatment.

Albrecht TA, Keim-Malpass J, Boyiadzis M, Rosenzweig M.

J Hosp Palliat Nurs. 2019 Apr;21(2):167-173. doi: 10.1097/NJH.0000000000000545.

PMID:
30829935
3.

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.

Boyiadzis MM, Dhodapkar MV, Brentjens RJ, Kochenderfer JN, Neelapu SS, Maus MV, Porter DL, Maloney DG, Grupp SA, Mackall CL, June CH, Bishop MR.

J Immunother Cancer. 2018 Dec 4;6(1):137. doi: 10.1186/s40425-018-0460-5. Review.

4.

Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival.

Alousi A, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Pidala J, Anderlini P, Boyiadzis M, Bredeson CN, Cahn JY, Cairo MS, Gadalla SM, Hashmi SK, Gale RP, Kanda J, Kamble RT, Kharfan-Dabaja MA, Litzow MR, Ringden O, Saad AA, Schultz KR, Verdonck LF, Waller EK, Yared JA, Holtan SG, Weisdorf DJ.

Biol Blood Marrow Transplant. 2019 Feb;25(2):270-278. doi: 10.1016/j.bbmt.2018.09.004. Epub 2018 Oct 3.

PMID:
30292009
5.

Acute Myeloid Leukemia Following Gynecologic Cancer in the Era of Platinum-Based Chemotherapy.

Nasioudis D, Lontos K, Tsagianni A, Boyiadzis M, Ko EM.

Int J Gynecol Cancer. 2018 Oct;28(8):1639-1642. doi: 10.1097/IGC.0000000000001338.

PMID:
30095705
6.

Location matters in early stage nodal diffuse large B-cell lymphoma.

Lontos K, Tsagianni A, Yuan JM, Normolle DP, Boyiadzis M, Hou JZ, Swerdlow SH, Dorritie KA.

Leuk Lymphoma. 2019 Jan;60(1):250-253. doi: 10.1080/10428194.2018.1471600. Epub 2018 Jun 22. No abstract available.

PMID:
29932787
7.

Exosomes in acute myeloid leukemia inhibit hematopoiesis.

Boyiadzis M, Whiteside TL.

Curr Opin Hematol. 2018 Jul;25(4):279-284. doi: 10.1097/MOH.0000000000000439. Review.

PMID:
29846239
8.

Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.

Boyiadzis MM, Kirkwood JM, Marshall JL, Pritchard CC, Azad NS, Gulley JL.

J Immunother Cancer. 2018 May 14;6(1):35. doi: 10.1186/s40425-018-0342-x.

9.

A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia.

Redner RL, Beumer JH, Kropf P, Agha M, Boyiadzis M, Dorritie K, Farah R, Hou JZ, Im A, Lim SH, Raptis A, Sehgal A, Christner SM, Normolle D, Johnson DE.

Leuk Lymphoma. 2018 Nov;59(11):2595-2601. doi: 10.1080/10428194.2018.1443330. Epub 2018 Apr 4.

PMID:
29616864
10.

Circulating exosomes carrying an immunosuppressive cargo interfere with cellular immunotherapy in acute myeloid leukemia.

Hong CS, Sharma P, Yerneni SS, Simms P, Jackson EK, Whiteside TL, Boyiadzis M.

Sci Rep. 2017 Oct 31;7(1):14684. doi: 10.1038/s41598-017-14661-w.

11.

Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia.

Boyiadzis M, Agha M, Redner RL, Sehgal A, Im A, Hou JZ, Farah R, Dorritie KA, Raptis A, Lim SH, Wang H, Lapteva N, Mei Z, Butterfield LH, Rooney CM, Whiteside TL.

Cytotherapy. 2017 Oct;19(10):1225-1232. doi: 10.1016/j.jcyt.2017.07.008. Epub 2017 Aug 30.

PMID:
28864289
12.

Intracranial Hemorrhage in Patients Newly Diagnosed with Acute Myeloid Leukemia and Hyperleukocytosis.

Lieberman F, Villgran V, Normolle D, Boyiadzis M.

Acta Haematol. 2017;138(2):116-118. doi: 10.1159/000478690. Epub 2017 Sep 1. No abstract available.

PMID:
28858876
13.

Response commentary: exosomes vs microvesicles in hematological malignancies.

Whiteside TL, Boyiadzis M.

Leukemia. 2017 Oct;31(10):2277. doi: 10.1038/leu.2017.248. Epub 2017 Aug 4. No abstract available.

14.

Outcomes of patients diagnosed with acute myeloid leukemia after solid organ transplantation.

Lontos K, Agha M, Raptis A, Hou JZ, Farah R, Redner RL, Im A, Dorritie KA, Sehgal A, Rossetti J, Saul M, Gooding WE, Humar A, Boyiadzis M.

Clin Transplant. 2017 Sep;31(9). doi: 10.1111/ctr.13052. Epub 2017 Aug 9.

PMID:
28710776
15.

Intensive induction chemotherapy vs hypomethylating agent-based regimen in patients aged ≥70 years with newly diagnosed acute myeloid leukemia.

Lim MJ, Agha A, Im A, Raptis A, Hou JZ, Boyiadzis M, Sehgal AR, Redner RL, Dorritie K, Marks SS, Agha ME, Lim SH.

Hematol Oncol. 2018 Apr;36(2):495-497. doi: 10.1002/hon.2456. Epub 2017 Jun 30. No abstract available.

PMID:
28664979
16.

The emerging roles of tumor-derived exosomes in hematological malignancies.

Boyiadzis M, Whiteside TL.

Leukemia. 2017 Jun;31(6):1259-1268. doi: 10.1038/leu.2017.91. Epub 2017 Mar 21. Review.

PMID:
28321122
17.

Patient and family caregiver dyadic adherence to the allogeneic hematopoietic cell transplantation medical regimen.

Posluszny DM, Bovbjerg DH, Agha ME, Hou JZ, Raptis A, Boyiadzis MM, Dunbar-Jacob J, Schulz R, Dew MA.

Psychooncology. 2018 Jan;27(1):354-358. doi: 10.1002/pon.4393. Epub 2017 Mar 8. No abstract available.

18.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.

Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV.

J Immunother Cancer. 2016 Dec 20;4:90. doi: 10.1186/s40425-016-0188-z. eCollection 2016.

19.

Leukapheresis in patients newly diagnosed with acute myeloid leukemia.

Villgran V, Agha M, Raptis A, Hou JZ, Farah R, Lim SH, Redner RL, Im A, Sehgal A, Dorritie KA, Kiss JE, Normolle D, Boyiadzis M.

Transfus Apher Sci. 2016 Oct;55(2):216-220. doi: 10.1016/j.transci.2016.07.001. Epub 2016 Jul 14.

PMID:
27470709
20.

Symptom Management and Psychosocial Needs of Adults With Acute Myeloid Leukemia During Induction Treatment: A Pilot Study.

Albrecht TA, Boyiadzis M, Elswick RK Jr, Starkweather A, Rosenzweig M.

Cancer Nurs. 2017 Nov/Dec;40(6):E31-E38. doi: 10.1097/NCC.0000000000000428.

21.

ICU intervention during induction chemotherapy for adult patients with newly diagnosed acute myeloid leukemia.

Hartsock B, Lim MJ, Roth CG, Raptis N, Weber D, Sehgal A, Boyiadzis M, Raptis A, Hou JZ, Im A, Dorritie K, Marks S, Agha M, Lim SH.

Leuk Res. 2016 Sep;48:16-9. doi: 10.1016/j.leukres.2016.07.001. Epub 2016 Jul 7.

PMID:
27442892
22.

Mitoxantrone and Etoposide for the Treatment of Acute Myeloid Leukemia Patients in First Relapse.

Im A, Amjad A, Agha M, Raptis A, Hou JZ, Farah R, Lim S, Sehgal A, Dorritie KA, Redner RL, McLaughlin B, Shuai Y, Duggal S, Boyiadzis M.

Oncol Res. 2016;24(2):73-80. doi: 10.3727/096504016X14586627440156.

PMID:
27296947
23.

Plasma-derived exosomes in acute myeloid leukemia for detection of minimal residual disease: are we ready?

Boyiadzis M, Whiteside TL.

Expert Rev Mol Diagn. 2016 Jun;16(6):623-9. doi: 10.1080/14737159.2016.1174578. Epub 2016 Apr 25. Review.

24.

Isolation of biologically active and morphologically intact exosomes from plasma of patients with cancer.

Hong CS, Funk S, Muller L, Boyiadzis M, Whiteside TL.

J Extracell Vesicles. 2016 Mar 24;5:29289. doi: 10.3402/jev.v5.29289. eCollection 2016.

25.

Hypomethylating Agents for Relapse after Allogeneic Hematopoietic Cell Transplantation in Myeloid Malignancies: A Case Series and Review of the Literature.

Im A, Raptis A, Hou JZ, Tompkins C, Winfield M, Guay M, Boyiadzis M, Agha M.

Acta Haematol. 2016;135(4):232-7. doi: 10.1159/000444118. Epub 2016 Mar 24.

PMID:
27007668
26.

Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.

Borthakur G, Popplewell L, Boyiadzis M, Foran J, Platzbecker U, Vey N, Walter RB, Olin R, Raza A, Giagounidis A, Al-Kali A, Jabbour E, Kadia T, Garcia-Manero G, Bauman JW, Wu Y, Liu Y, Schramek D, Cox DS, Wissel P, Kantarjian H.

Cancer. 2016 Jun 15;122(12):1871-9. doi: 10.1002/cncr.29986. Epub 2016 Mar 18. Erratum in: Cancer. 2016 Oct 15;122(20):3246.

27.

Flow Cytometric Evaluation of Double/Triple Hit Lymphoma.

Roth CG, Gillespie-Twardy A, Marks S, Agha M, Raptis A, Hou JZ, Farah R, Lin Y, Qian Y, Pantanowitz L, Boyiadzis M.

Oncol Res. 2016;23(3):137-46. doi: 10.3727/096504015X14500972666761.

PMID:
26931436
28.

Generating Peripheral Blood Derived Lymphocytes Reacting Against Autologous Primary AML Blasts.

Mehta RS, Chen X, Antony J, Boyiadzis M, Szabolcs P.

J Immunother. 2016 Feb-Mar;39(2):71-80. doi: 10.1097/CJI.0000000000000107.

29.

Natural killer cell (NK) subsets and NK-like T-cell populations in acute myeloid leukemias and myelodysplastic syndromes.

Aggarwal N, Swerdlow SH, TenEyck SP, Boyiadzis M, Felgar RE.

Cytometry B Clin Cytom. 2016 Jul;90(4):349-57. doi: 10.1002/cyto.b.21349. Epub 2016 Feb 3.

30.

AML treatment in older adults.

Sehgal A, Boyiadzis M.

Aging (Albany NY). 2015 Sep;7(9):611-2. No abstract available.

31.

Immunotherapy for acute leukemia.

Boyiadzis M, Whiteside TL, Pavletic SZ.

Aging (Albany NY). 2015 Jun;7(6):354-5. No abstract available.

32.

Programmed death-1 checkpoint blockade in acute myeloid leukemia.

Sehgal A, Whiteside TL, Boyiadzis M.

Expert Opin Biol Ther. 2015;15(8):1191-203. doi: 10.1517/14712598.2015.1051028. Epub 2015 Jun 3. Review.

33.

Outcomes of acute myeloid leukemia with t(15;17) not associated with acute promyelocytic leukemia.

Soni A, Djokic M, Hou JZ, Redner RL, Boyiadzis M.

Leuk Lymphoma. 2015;56(11):3236-9. doi: 10.3109/10428194.2015.1036262. Epub 2015 May 20. Review. No abstract available.

PMID:
25860246
34.

Chondroitin sulfate proteoglycan-4 (CSPG4)-specific monoclonal antibody 225.28 in detection of acute myeloid leukemia blasts.

Fenton M, Whiteside TL, Ferrone S, Boyiadzis M.

Oncol Res. 2015;22(2):117-21. doi: 10.3727/096504014X14174484758503.

PMID:
25706398
35.

Intensive chemotherapy in patients aged 70 years or older newly diagnosed with acute myeloid leukemia.

Ross K, Gillespie-Twardy AL, Agha M, Raptis A, Hou JZ, Farah R, Redner RL, Im A, Duggal S, Ding F, Lin Y, Boyiadzis M.

Oncol Res. 2015;22(2):85-92. doi: 10.3727/096504014X14146137738547.

PMID:
25706395
36.

Information transfer by exosomes: A new frontier in hematologic malignancies.

Boyiadzis M, Whiteside TL.

Blood Rev. 2015 Sep;29(5):281-90. doi: 10.1016/j.blre.2015.01.004. Epub 2015 Jan 30. Review.

PMID:
25686749
37.

You eat what you are: autophagy inhibition as a therapeutic strategy in leukemia.

Sehgal AR, Konig H, Johnson DE, Tang D, Amaravadi RK, Boyiadzis M, Lotze MT.

Leukemia. 2015 Mar;29(3):517-25. doi: 10.1038/leu.2014.349. Epub 2014 Nov 26. Review.

38.

Center for International Blood and Marrow Transplant Research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohort.

Arora M, Hemmer MT, Ahn KW, Klein JP, Cutler CS, Urbano-Ispizua A, Couriel DR, Alousi AM, Gale RP, Inamoto Y, Weisdorf DJ, Li P, Antin JH, Bolwell BJ, Boyiadzis M, Cahn JY, Cairo MS, Isola LM, Jacobsohn DA, Jagasia M, Klumpp TR, Petersdorf EW, Santarone S, Schouten HC, Wingard JR, Spellman SR, Pavletic SZ, Lee SJ, Horowitz MM, Flowers ME.

Biol Blood Marrow Transplant. 2015 Apr;21(4):640-5. doi: 10.1016/j.bbmt.2014.10.022. Epub 2014 Dec 18.

39.

Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia.

Boyiadzis M, Arora M, Klein JP, Hassebroek A, Hemmer M, Urbano-Ispizua A, Antin JH, Bolwell BJ, Cahn JY, Cairo MS, Cutler CS, Flowers ME, Gale RP, Herzig R, Isola LM, Jacobsohn DA, Jagasia MH, Klumpp TR, Lee SJ, Petersdorf EW, Santarone S, Spellman SR, Schouten HC, Verdonck LF, Wingard JR, Weisdorf DJ, Horowitz MM, Pavletic SZ.

Clin Cancer Res. 2015 May 1;21(9):2020-8. doi: 10.1158/1078-0432.CCR-14-0586. Epub 2014 Oct 27.

40.

Isolation and characterization of CD34+ blast-derived exosomes in acute myeloid leukemia.

Hong CS, Muller L, Boyiadzis M, Whiteside TL.

PLoS One. 2014 Aug 5;9(8):e103310. doi: 10.1371/journal.pone.0103310. eCollection 2014.

41.

Plasma exosomes as markers of therapeutic response in patients with acute myeloid leukemia.

Hong CS, Muller L, Whiteside TL, Boyiadzis M.

Front Immunol. 2014 Apr 10;5:160. doi: 10.3389/fimmu.2014.00160. eCollection 2014.

42.

DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies.

Im AP, Sehgal AR, Carroll MP, Smith BD, Tefferi A, Johnson DE, Boyiadzis M.

Leukemia. 2014 Sep;28(9):1774-83. doi: 10.1038/leu.2014.124. Epub 2014 Apr 4. Review. Erratum in: Leukemia. 2015 Feb;29(2):516.

43.

TIM3 expression by leukemic and non-leukemic myeloblasts.

Roth CG, Garner K, Eyck ST, Boyiadzis M, Kane LP, Craig FE.

Cytometry B Clin Cytom. 2013 May;84(3):167-72. doi: 10.1002/cyto.b.21080. Epub 2013 Mar 29.

44.

Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy.

McLaughlin B, Im A, Raptis A, Agha M, Hou JZ, Redner R, Duggal S, Lin Y, Smith C, Boyiadzis M.

Int J Hematol. 2012 Dec;96(6):743-7. doi: 10.1007/s12185-012-1192-9. Epub 2012 Nov 7.

PMID:
23132594
45.

CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations.

Rollins-Raval M, Pillai R, Warita K, Mitsuhashi-Warita T, Mehta R, Boyiadzis M, Djokic M, Kant JA, Roth CG.

Appl Immunohistochem Mol Morphol. 2013 May;21(3):212-7. doi: 10.1097/PAI.0b013e318261a342.

PMID:
22914610
46.

Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia.

Foon KA, Mehta D, Lentzsch S, Kropf P, Marks S, Lenzner D, Pietragallo L, Sulecki M, Tarhini A, Boyiadzis M.

Blood. 2012 Mar 29;119(13):3184-5. doi: 10.1182/blood-2012-01-408047. No abstract available.

47.

Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.

Lentzsch S, O'Sullivan A, Kennedy RC, Abbas M, Dai L, Pregja SL, Burt S, Boyiadzis M, Roodman GD, Mapara MY, Agha M, Waas J, Shuai Y, Normolle D, Zonder JA.

Blood. 2012 May 17;119(20):4608-13. doi: 10.1182/blood-2011-12-395715. Epub 2012 Mar 26.

48.

F-box protein FBXL2 targets cyclin D2 for ubiquitination and degradation to inhibit leukemic cell proliferation.

Chen BB, Glasser JR, Coon TA, Zou C, Miller HL, Fenton M, McDyer JF, Boyiadzis M, Mallampalli RK.

Blood. 2012 Mar 29;119(13):3132-41. doi: 10.1182/blood-2011-06-358911. Epub 2012 Feb 8.

49.

Improved clinical trial enrollment in adolescent and young adult (AYA) oncology patients after the establishment of an AYA oncology program uniting pediatric and medical oncology divisions.

Shaw PH, Boyiadzis M, Tawbi H, Welsh A, Kemerer A, Davidson NE, Ritchey AK.

Cancer. 2012 Jul 15;118(14):3614-7. doi: 10.1002/cncr.26634. Epub 2011 Dec 27.

50.

Primary central nervous system post-transplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation.

Lieberman F, Yazbeck V, Raptis A, Felgar R, Boyiadzis M.

J Neurooncol. 2012 Apr;107(2):225-32. doi: 10.1007/s11060-011-0739-6. Epub 2011 Oct 26. Review.

PMID:
22037801

Supplemental Content

Loading ...
Support Center